Cancer Research

#Cancer drug targets #Collaboration #Drug discovery #Molecular glue degrader #Protein #Rappta Therapeutics #SpringWorks Therapeutics

License agreement for molecular glue targeting PP2A

Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More

#Business & Investment #Cancer Research #News

Gastrointestinal tract
#Gastrointestinal #GSK #Mergers and acquisitions #Oncology

GSK grows gastrointestinal cancers portfolio with new acquisition

GSK has revealed it will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).  Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment.   The… Read More

#Business & Investment #Cancer Research #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News

Gene therapy concept
#Blood cancer #CAR-T #Cell therapy #Regenerative Medicine #Stem cells #Tune Therapeutics

Unlocking the future of medicine with cell therapy

Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More

#Cancer Research #Exclusive Content #Opinion

Breast cancer cell
#Breast cancer #Cancer research #Gene mutation #National Institute for Health and Care Excellence (NICE) #Regulatory

NICE approves first ESR1-mutated metastatic breast cancer drug

Final draft guidance from the UK’s National Institute for Health and Care Excellence (NICE) recommends the use of elacestrant, the first tailored treatment for locally advanced and metastatic breast cancer with mutations in the ESR1 gene. Specifically, the drug will be available on the NHS to treat post-menopausal women, and… Read More

#Cancer Research #News #Regulatory

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News

#AACR #Cancer research #Clinical trials #Monotherapy #Recursion #Solid tumours

Encouraging response for monotherapy dose-escalation study

Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More

#Cancer Research #News

Medical professional examining mammogram
#Breast cancer #Molecular glue degrader #Monte Rosa Therapeutics #Oncology

Selective oral CDK2 degrader shows promise in breast cancer models

According to new data, a cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader (MGD) drove deep tumour regression in preclinical models of HR-positive/HER2-negative breast cancer.  Monte Rosa Therapeutics will present the preclinical data at the 2024 San Antonio Breast Cancer Symposium, held 10-13 December in San Antonio, Texas. Read More

#Cancer Research #News

Blood cancer
#Blood cancer #CAR-T #Cell therapy #Haematology #Oncology #Phase I trial #Synthekine

Positive initial results from trial of CD19 CAR-T in blood cancers

Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.  In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More

#Cancer Research #News

Diamond Light Source's synchrotron
#Cancer Research Horizons #Diamond Light Source #Fragment-based drug discovery #Oncology #Partnership

UK partners establish fragment-based drug discovery programme

Cancer Research Horizons is partnering with Diamond Light Source, the UK’s national synchrotron, to build a world-leading fragment-based drug discovery programme.  Diamond Light Source accelerates electrons to near light speed, producing bright light that is directed into research instruments known as beamlines.   Cancer Research Horizons… Read More

#Business & Investment #Cancer Research #News

Gold compound
#Drug resistance #Oncology #Ovarian cancer #RMIT University #Solid tumours

Gold-based drug slows tumour growth by 82%

Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research.  The study published in the European Journal of Medicinal Chemistry reveals a new gold-based compound that’s 27 times… Read More

#Cancer Research #Editor's Choice #News

CAR-T cells attack cancer cells
#Autolus #Blood cancer #CAR-T #Cell therapy #Leukaemia #Oncology #University College London

Next-generation therapy overcomes limitations of other CAR-T

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).  The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More

#Cancer Research #Editor's Choice #News

#Brain cancer #Genetic profiling #Machine learning #Oncology #Precision medicine #UCLA

ML study identifies new glioblastoma treatment strategy

A new precision medicine approach that combines genetic and functional profiling could predict how glioblastoma will respond to therapy.  A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma becomes resistant to treatment and introduces a new approach that paves… Read More

#Cancer Research #Editor's Choice #News

#Cancer therapeutics #Cancer vaccine #Immunotherapy #mRNA-based vaccines #Oncology

A deep dive into cancer vaccines

Megan Thomas explores the innovation and opportunity for cancer vaccines with Dr Alexander Zehnder, CEO of CureVac, and Dr Chris Haqq, Chief Medical Officer of Elicio Therapeutics. It could be argued that Covid-19 gave us a boost to start making headway in cancer vaccines. Between the acceleration of mRNA vaccine… Read More

#Cancer Research #Exclusive Content

Genomics
#Gene sequencing #Genetics / genomics #Oncology #The Institute of Cancer Research

Whole-genome sequencing reveals new potential cancer-driving genes

Researchers have identified 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options and provide hope that existing cancer treatments, such as PARP inhibitors, could be extended to thousands more patients. Read More

#Cancer Research #Editor's Choice #News